



Opdivo® (nivolumab), Yervoy® (ipilimumab) – New indication

- On October 2, 2020, the [FDA announced](#) the approval of [Bristol-Myers Squibb's Opdivo \(nivolumab\)](#) in combination with [Yervoy \(ipilimumab\)](#), for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma (MPM).
- Opdivo is also approved for unresectable or metastatic melanoma, adjuvant treatment of melanoma, metastatic non-small cell lung cancer, small cell lung cancer, advanced renal cell carcinoma, classical Hodgkins lymphoma, squamous cell carcinoma of the head and neck, urothelial carcinoma, microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer, hepatocellular carcinoma, and esophageal squamous cell carcinoma.
- Yervoy is also approved for unresectable or metastatic melanoma, adjuvant treatment of melanoma, advanced renal cell carcinoma, microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer, hepatocellular carcinoma, and metastatic non-small cell lung cancer.
- MPM is a life-threatening cancer of the lungs' lining caused by inhaling asbestos fibers that about 20,000 Americans are diagnosed with each year. MPM accounts for most mesothelioma diagnoses, and most patients have an unresectable tumor at time of diagnosis. With currently available therapy, overall survival is generally poor.
- The approval of Opdivo plus Yervoy for the new indication was based on CHECKMATE-743, a randomized, open-label study in 605 patients with unresectable MPM. Patients received intravenous (IV) infusions of Opdivo every two weeks with IV infusions of Yervoy every six weeks for up to two years, or platinum-doublet chemotherapy for up to six cycles. The primary efficacy outcome measure was overall survival (OS). Additional efficacy outcome measures included progression-free survival (PFS), overall response rate (ORR), and duration of response (DOR).
 - Median OS was 18.1 months and 14.1 months for Opdivo plus Yervoy vs. chemotherapy, respectively (hazard ratio [HR] 0.74, 95% CI: 0.61, 0.89; p = 0.002).
 - Median PFS was 6.8 months vs. 7.2 months for Opdivo plus Yervoy vs. chemotherapy, respectively (HR 1.0, 95% CI: 0.82, 1.21).
 - The ORR was 40% (95% CI: 34, 45) vs. 43% (95% CI: 37, 49) for Opdivo plus Yervoy vs. chemotherapy, respectively.
 - Median DOR was 11.0 months (95% CI: 8.1, 16.5) vs. 6.7 (95% CI: 5.3, 7.1) for Opdivo plus Yervoy vs. chemotherapy, respectively.
- The recommended dose of Opdivo for the treatment of MPM is 360 mg every 3 weeks (30-minute IV infusion). The recommended dose of Yervoy is 1 mg/kg every 6 weeks (30-minute IV infusion). Treatment should be continued until disease progression, unacceptable toxicity, or up to 2 years in patients without disease progression.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2020 Optum, Inc. All rights reserved.



- Refer to the Opdivo and Yervoy drug labels for dosing for their other indications.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](https://www.optum.com).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2020 Optum, Inc. All rights reserved.